Announced Date: 2025-03-25 (March 25, 2025)
Asset Name: HRS-5346
Licensor: Hengrui Pharma (Jiangsu Hengrui Pharmaceuticals Co., China)
Licensee (Buyer): MSD （Merck & Co., Inc，USA）
.
Asset Modality: Small Molecule, oral
Asset Target: Lipoprotein(a) inhibitor , or Lp(a) inhibitor
Current Stage: Phase II, China
.
Scope of Authority:
Hengrui Pharma has granted MSD exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region(China Mainland, Hong Kong, Macau and Taiwan)
.
Deal Detail:
Upfront payment of $200 million,
Milestone payments up to approximately $1.77 billion.
Total 1.97 billion plus
Royalties on net sales, tiered
.
Link:
MSD Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
